The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Manually producing the TLF involves an interplay of biostatisticians, terminology coders, statistical programmers, and ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s own blood is modified at the bedside, or allogeneic therapies, created with ...

They are following in the footsteps of NHS chief executive Amanda Pritchard and medical director Sir Stephen Powis, who have ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...